CJC-1295 DAC vs No DAC: Research and Buying Guide

Laboratories comparing extended and short-acting GHRH research models can find CJC-1295 DAC for sale through specialized U.S. research suppliers. Growth Hormone-Releasing Hormone (GHRH) analogues represent an established subject of study in endocrine research. Among these agents, CJC-1295 and related sequence variants are frequently evaluated for their ability to interact with the pituitary GHRH receptor. Understanding the structural differences, pharmacokinetic profiles, and analytical criteria for these compounds is essential when designing controlled laboratory protocols.

1. Quick Answer: Structural Distinction and Albumin Binding

The fundamental difference between CJC-1295 with DAC and its non-DAC counterpart lies in the presence of the Drug Affinity Complex (DAC).

• CJC-1295 with DAC features a maleimidopropionyl linker attached to a lysine residue at the C-terminus of a tetrasubstituted peptide backbone, enabling covalent binding to circulating serum albumin (bioconjugation). This process protects the peptide from rapid enzymatic degradation and renal elimination.
• Non-DAC variants lack this reactive linker, resulting in a significantly shorter duration of systemic exposure following administration in experimental models.

2. Naming Clarification: CJC-1295, Modified GRF 1-29, and Sermorelin

In academic literature and commercial cataloguing, terminology surrounding GHRH derivatives is sometimes used inconsistently. To maintain scientific clarity:

1. Sermorelin: A synthetic amidated peptide corresponding to the biologically active N-terminal 1–29 fragment of human GHRH. It is related to endogenous 44-amino-acid GHRH but should not be described as a separately occurring natural 29-amino-acid hormone.
2. Modified GRF 1-29: A tetrasubstituted analogue of GHRH(1-29) commonly described as containing D-Ala², Gln⁸, Ala¹⁵ and Leu²⁷ substitutions designed to improve resistance to enzymatic degradation.
3. CJC-1295 with DAC: Specifically designates the tetrasubstituted Modified GRF 1-29 sequence with the addition of the Lys-linked maleimidopropionyl DAC moiety.

Calling Modified GRF 1-29 “CJC-1295 without DAC” is common in commercial settings, but researchers should confirm exact sequence details in supplier documentation to prevent ambiguity.

3. Human Research Data: What Is Established for CJC-1295 with DAC

Pharmacokinetic parameters for CJC-1295 with DAC were evaluated in two randomized, placebo-controlled, double-blind ascending-dose trials reported by Teichman et al. (2006) [1]. These trials provided quantitative pharmacokinetic and pharmacodynamic data in healthy adults:

• Estimated Half-Life: Approximately 5.8–8.1 days in the reported healthy-adult studies [1].
• GH and IGF-1 Response: Mean plasma growth hormone (GH) concentrations increased in a dose-dependent manner and remained elevated for six days or longer, while mean IGF-1 concentrations remained elevated for approximately 9–11 days [1].
• Pulsatility Profile: CJC-1295 with DAC produced prolonged elevation of basal and mean GH exposure [1]. A small short-duration human study reported that endogenous pulsatile secretion remained detectable during this sustained exposure, so the profile should not be described as completely non-pulsatile [3].

4. Characteristics of Non-DAC Variants (Modified GRF 1-29)

Modified GRF 1-29 is generally characterized as the shorter-acting, non-albumin-binding variant. Researchers evaluating CJC-1295 without DAC often select it for protocols requiring acute, transient receptor activation.

Commonly cited half-life estimates are much shorter than those reported for CJC-1295 with DAC, but direct comparative human evidence is limited. Because it lacks the albumin-binding DAC moiety, it is expected to clear considerably faster than the DAC-conjugated form despite the stabilizing substitutions in its peptide backbone.

5. Dual-Receptor Considerations and Combination Formulations

Growth hormone secretion is regulated by complementary pathways, primarily GHRH receptor signaling and Growth Hormone Secretagogue Receptor (GHS-R1a) signaling.

GHRH-receptor agonists and ghrelin-receptor agonists act through complementary signaling pathways. Some experimental models have reported a greater GH response during combined stimulation, but the magnitude and secondary endocrine effects depend on the compound, model and study design. When investigating dual-component mixtures—such as a CJC-1295 and Ipamorelin blend—investigators should ensure that component ratios, purity, and individual constituent identities are explicitly documented.

6. Direct Side-by-Side Comparison Matrix

7. Quality Evaluation Standards: Analytical Documentation and Handling

When procuring research peptides, quality assessment relies on verifiable laboratory documentation rather than visual inspection or subjective claims.

• HPLC and Mass Spectrometry: HPLC supports an assessment of chromatographic purity, while MS indicates whether the observed molecular mass is consistent with the expected compound. A standard COA does not necessarily establish full sequence identity, quantitative content, sterility, endotoxin levels or biological activity.
• Packaging and Certificate of Analysis (COA): Packaging should be intact, correctly labeled and matched to the relevant batch documentation. Visual appearance alone cannot establish peptide identity or purity. Certificates of Analysis should originate from an identifiable laboratory.
• Storage and Handling: Storage, solvent compatibility and handling conditions should follow the documentation supplied for the specific compound, formulation and batch.

8. Summary & Conclusion

The two variants represent different research materials rather than interchangeable versions of the same product. Supplier documentation, batch identification and appropriate analytical data should be evaluated before either material is incorporated into a controlled protocol.

Frequently Asked Questions (FAQ)

Q: Is CJC-1295 DAC identical to Modified GRF 1-29?

A: No. While both share a similar tetrasubstituted 29-amino-acid backbone, CJC-1295 DAC contains a Lys-linked maleimidopropionyl linker that enables albumin binding and extends in vivo circulation duration.

Q: What does a Certificate of Analysis (COA) indicate?

A: HPLC supports an assessment of chromatographic purity, while MS indicates whether the observed molecular mass is consistent with the expected compound. A standard COA does not necessarily establish full sequence identity, quantitative content, sterility, endotoxin levels or biological activity.

References

1. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
2. Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., & Bridon, D. P. (2005). Human growth hormone-releasing factor (hGRF)1–29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058. https://doi.org/10.1210/en.2004-1286
3. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702

Important Notice: The compounds discussed are intended strictly for controlled laboratory research and analytical evaluation. They are not intended for human or animal consumption, clinical use, veterinary use or self-administration.